Molecular Partners AG's SEC filings document a foreign private issuer developing DARPin therapeutics for oncology, including targeted radiopharmaceuticals and immune-engaging protein drug candidates. Its Form 6-K reports furnish press releases, annual report materials, clinical and preclinical program updates, financial results, and scientific disclosures tied to candidates such as MP0712, MP0317, MP0533 and other DARPin programs.
The filings also cover shareholder-meeting materials, board elections, compensation votes, consolidated financial statements, and incorporation of certain Form 6-K exhibits into registration statements. Annual report disclosures describe the company's pipeline, partnerships, research and development focus, cash resources, governance framework, and public-company reporting as a Swiss issuer listed on SIX and Nasdaq.
Molecular Partners reported unaudited Q1 2026 results showing continued investment in its oncology pipeline and a smaller loss than a year ago. The company generated no revenue, while research and development expenses were CHF 9.4 million and selling, general and administrative expenses were CHF 4.0 million, leading to an operating loss of CHF 13.4 million and a net loss of CHF 13.1 million (CHF 0.35 per share).
Cash, cash equivalents and short-term time deposits totaled CHF 79 million (approximately USD 100 million) as of March 31, 2026, which is expected to fund operations into late 2027 under current assumptions. During the quarter, a Phase 1/2a study of lead Radio-DARPin MP0712 began enrolling, a Phase 2 study of MP0317 in cholangiocarcinoma started, MP0533 showed ongoing preliminary activity in AML, and preclinical Switch-DARPin candidate MP0632 produced encouraging tumor regression data.
Molecular Partners AG filed a Form 6-K highlighting new Phase 1 results for its tumor-localized CD40 agonist MP0317 and ongoing Phase 2 development. A peer-reviewed paper in Nature Cancer reports that MP0317 activated the CD40 pathway within the tumor microenvironment and showed evidence of tumor microenvironment remodeling in patients with advanced solid tumors.
In the 46-patient Phase 1 monotherapy study, MP0317 demonstrated a favorable safety profile up to the highest tested dose and pharmacokinetics compatible with weekly or every-three-week dosing. One patient achieved an unconfirmed partial response and 14 patients achieved stable disease. An investigator-initiated, randomized Phase 2 trial in front-line cholangiocarcinoma is open with eight sites activated, targeting 75 patients to compare standard-of-care chemotherapy plus durvalumab with or without MP0317.
Molecular Partners AG reported outcomes from its Annual General Meeting, where shareholders elected Clare Fisher to the Board of Directors and approved all Board proposals by a wide majority. Fisher brings more than two decades of healthcare experience, including senior business development and M&A roles at several pharmaceutical and biotech companies.
Shareholders approved the 2025 IFRS consolidated and statutory financial statements, the consultative vote on the compensation report, and the proposal to carry forward the 2025 net loss of CHF 57,853,768, increasing the loss carried forward to CHF 257,293,925. The Board and Management Board were granted discharge for 2025. Steven H. Holtzman did not stand for re-election after 12 years on the Board, while all other directors were re-elected, including Bill Burns as Chairman. KPMG AG was re-elected as statutory auditor for 2026, and Anwaltskanzlei Keller AG as independent proxy until the 2027 AGM. All binding compensation motions for the Board and Management Board were also approved.
Molecular Partners AG has published the invitation to its 2026 Annual General Meeting and proposes Clare Fisher for election to the Board of Directors. The meeting will be held on April 14, 2026, in Schlieren, Switzerland.
Fisher is SVP for Global Business Development and M&A at BeOne Medicines and has over two decades of leadership experience across business development, M&A and strategy in the biotech and pharmaceutical industry. Current Board member Steven H. Holtzman will not stand for re-election after 12 years of service, with the Chair and CEO highlighting his role in key partnerships, listings and COVID drug efforts.
The company also provides a 2026 financial reporting calendar, including an interim management statement for Q1 on May 12, 2026, half-year results on August 25, 2026, and a Q3 interim management statement on October 29, 2026.
Molecular Partners reported full-year 2025 results alongside major advances in its DARPin pipeline. Lead Radio-DARPin MP0712 entered a US Phase 1/2a trial for DLL3-positive small cell lung and other neuroendocrine cancers, with initial clinical data expected in 2026. Second radio program MP0726 targeting mesothelin is moving toward first-in-human imaging, and a new Switch-DARPin immune engager candidate is planned for nomination in H1 2026. MP0317 is in a randomized Phase 2 cholangiocarcinoma study and MP0533 continues in a Phase 1/2a AML trial, with a development update planned in H1 2026.
Financially, the company generated no revenue in 2025 and recorded total operating expenses of CHF 58.1 million, resulting in a net loss of CHF 61.7 million. Cash and short-term time deposits were CHF 93.1 million as of December 31, 2025, which management expects to fund operations into 2028. Operating expenses for 2026 are guided to CHF 45–55 million, and the balance sheet remained debt-free at year-end.
Molecular Partners reports 2025 results showing a deeper net loss alongside disciplined cost control and a solid cash position. Total revenues were CHF 0 million versus CHF 5.0 million in 2024 as a Novartis collaboration wound down, while operating expenses fell to CHF 58.1 million from CHF 66.1 million.
The net loss widened to CHF 61.7 million, or CHF 1.65 per share, compared with CHF 54.0 million in 2024. Cash and short‑term deposits totaled CHF 93.1 million as of December 31, 2025, funding operations into 2028, and headcount decreased to 134 FTE from 158.5.
The company advanced its DARPin pipeline, including the alpha‑emitting Radio‑DARPin MP0712 entering a Phase 1/2a trial, nomination of MP0726, progress on immune cell engagers MP0533 and Switch‑DARPins, and set 2026 operating expense guidance of CHF 45–55 million.
Molecular Partners files its annual report, outlining its DARPin-based drug development pipeline, key risks and financial position. The company reports cumulative losses of CHF 311.8 million as of December 31, 2025, including a CHF 61.7 million net loss in 2025 and CHF 54.0 million in 2024.
It states that existing cash, cash equivalents and expected collaboration funding are expected to finance operations into 2028, but it may need substantial additional capital to complete development and potential commercialization of its product candidates. The report emphasizes clinical, regulatory and competitive risks around oncology and radioligand programs, and notes 40,374,641 ordinary shares outstanding as of December 31, 2025.
Molecular Partners furnished a report highlighting new early clinical data for MP0712, its DLL3‑targeting Radio‑DARPin radiotherapy. First patient imaging and dosimetry results using the diagnostic isotope 203Pb in five patients with DLL3‑expressing cancers showed specific tumor uptake and limited accumulation in healthy tissues.
The findings, presented at the 8th Theranostics World Congress, support ongoing clinical development of MP0712 carrying the therapeutic isotope 212Pb, including a U.S. Phase 1/2a study designed to establish a recommended Phase 2 dose. Initial safety and activity data from this trial are expected in 2026.
Molecular Partners AG reports clinical pipeline progress and a solid cash position. The company had cash and cash equivalents of CHF 93.1 million as of December 31, 2025 (unaudited), which it expects will fund operations into 2028. Several programs are advancing: the Phase 1/2a trial of lead Radio-DARPin MP0712 in small cell lung cancer has started in the US, with first patient dosing expected in Q1 2026 and initial clinical data anticipated in 2026, supported by encouraging compassionate-use imaging that showed targeted tumor delivery.
The Radio-DARPin pipeline also includes MP0726 targeting mesothelin, with plans to move multiple radiotherapy programs toward first-in-human imaging and guidance from a newly formed scientific advisory board. An investigator-initiated Phase 2 trial of MP0317 in advanced cholangiocarcinoma is open in France, aiming to enroll 75 patients in combination with durvalumab plus chemotherapy. MP0533, a tetra-specific T cell engager for AML, is in an ongoing Phase 1/2a study, with densified dosing showing tolerability and preliminary antitumor activity and a development update planned for H1 2026. The company also plans to nominate a first Switch-DARPin candidate for development in H1 2026.